Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-8264 with SoC in Acute Graft-versus-Host Disease
NCT05673876Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GDC-8264 in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Genentech. Primary endpoints: Number of Participants With Adverse Events up to 9 months, Plasma Concentration of GDC-8264 at Day 29 and 3 more. Started Apr 2023; status: completed.
02
Drugs
GDC-8264
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05673876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673876.